Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403710 · ClinicalTrials.gov registry record
Botulinum Toxin Therapy in Hidradenitis Suppurativa
A clinical trial of Hidradenitis Suppurativa and Hyperhidrosis, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05403710: Recruiting study of Hidradenitis Suppurativa and Hyperhidrosis, sponsored by University of Massachusetts, Worcester.
NCT05403710 is a study of Hidradenitis Suppurativa and Hyperhidrosis that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05403710, a study of Hidradenitis Suppurativa and Hyperhidrosis, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Primary Outcome
immune cell phenotyping
Conditions Studied
Interventions
- DRUG Botulinum toxin
Study Locations (1)
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2028-04-30 |
What NCT05403710 shows while recruiting
NCT05403710 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin is the first listed.
NCT05403710 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05403710 about?
NCT05403710 is a clinical study titled "Botulinum Toxin Therapy in Hidradenitis Suppurativa". This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin re...
What is the current status of trial NCT05403710?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-06-07. Estimated completion is 2028-04-30.
What conditions does trial NCT05403710 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa, Hyperhidrosis.
What interventions are being tested in trial NCT05403710?
The interventions under investigation include: Botulinum toxin (DRUG).
Who is sponsoring clinical trial NCT05403710?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403710 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05403710's enrollment target sits among peer trials
20 41st of 52 higher than 9 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI